Soluble CD44: Quantification and molecular repartition in plasma of patients with colorectal cancer

British Journal of Cancer

Volumn 80, Issue 12, 1999, Pages 1995-2000

  Masson, D ^a,b   Denis, M G ^a,b   Denis, M ^b   Blanchard, D ^c   Loirat, M J ^c   Cassagnau, E ^b   Lustenberger, P ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b HÔTEL DIEU   (France)

^c Site de Nantes   (France)

Author keywords

Colorectal cancer; Plasma; Soluble CD44

Indexed keywords

HERMES ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOBLOTTING; ION EXCHANGE CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TUMOR GROWTH; WESTERN BLOTTING;

AGED; ANTIGENS, CD; ANTIGENS, CD44; BLOTTING, WESTERN; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTESTINAL DISEASES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; REFERENCE VALUES; SIGMOID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032814784     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690633     Document Type: Article

References (30)

1. Arch R, Wirth K, Hofmann M, Ponta H, Matzku S, Herrlich P and Z̈ller M (1992) Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 257: 682-685
2. Astler VB and Coller FA (1954)The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139: 846-851
3. Aruffo A, Stamenkovic I, Melnick M, Underhill CB and Seed B (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313
4. Bazil V and Strominger JL (1994) Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. J Immunol 152: 1314-1322
5. Blanchard D, Petit-LeRoux Y, Willem C and Loirat MJ (1997) Flow cytometry and immunoblotting analysis of monoclonal antibodies directed to CD-related antigens. Transfus Clin Biol 4: 153-156
6. Combaret V, Gross N, Lasset C, Frappaz D, Peruisseau G, Philip T, Beck D and Favrot MC (1996) Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 14: 25-34
7. De Rossi G, Marroni P, Paganuzzi M, Mauro FR, Tenca C, Zarcone D, Velardi A, Molica A and Grossi CE (1997) Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell lymphocytic leukemia. Leukemia 11: 134-141
8. Galmiche A and Lustenberger P (1994) CD44, invasion tumorale et métastase. Med Sci 10: 1282-1291
9. Gorham H, Sugino T, Woodman AC and Tarin D (1996) Cellular distribution of CD44 gene transcripts in colorectal carcinomas and in normal colonic mucosa. J Clin Pathol 49: 482-488
10. Gotley DC, Fawcett J, Walsh MD, Reeder JA, Simmons DL and Antalis TM (1996) Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Br J Cancer 74: 342-351
11. Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haußmann I, Matzku S, Wenzel A, Ponta H and Herrlich P (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells, Cell 65: 13-24
12. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J and Sy MS (1994) Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54: 422-426
13. Harn HJ, Ho LI, Shyu RY, Yuan JS, Lin FG, Young TH, Liu CA, Tang HS and Lee WH (1996) Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J Clin Gastroenterol 22: 107-110
14. Higashikawa K, Yokozaki H, Ue T, Taniyama K, Ishikawa T, Tarin D and Tahara E (1996) Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int J Cancer 66: 11-17
15. Huel S, Groux H, Caillou B, Valentin H, Prieur AM and Bernard A (1989) CD44 contributes to T cell activation. J Immunol 143: 798-801
16. Imazeki F, Yokosuka O, Yamaguchi T, Ohto M, Isono K and Omata M (1996) Expression of variant CD44-messenger RNA in colorectal adenocarcinomas and adenomatous polyps in humans. Gastroenterology 110: 362-368
17. Kan M, Kanayama HO, Naruo S, Tsuji M, Kojima K, Kurokawa Y and Kagawa S (1996) Serological evaluation of soluble CD44 in renal cancer. Jpn J Cancer Res 87: 1191-1194
18. Katoh S, McCarthy JB and Kincade PW (1994) Characterization of soluble CD44 in the circulation of mice. J Immunol 153: 3440-3449
19. Labarriere N, Piatl JP, Otry C, Denis M, Lustenberger P, Mcflah K and Le Pendu J (1994) Level of H-blood group expression in CD44v modulates lak cell lysis sensitivity and tumorigenicity of rat colon carcinoma cells. Cancer Res 54: 6275-6281
20. Lein M, Weiß S, Jung K, Schnorr D and Loening S (1996) Soluble CD44 variants in serum of patients with prostate cancer and other urological malignanctes. Prostate 29: 334-335
21. Lucas MG, Green AM and Telen MJ (1989) Characterization of serum /n (Lu)-related antigen: identification of a serum protein related to erythrocyte p80. Blood 73: 596-600
22. Martin S, Jansen F, Bokelmann J and Kolb H (1997) Soluble CD44 splice variants in metastasizing human breast cancer. Int J Cancer (Pred Oncol) 74: 443-445
23. Rafi A, Nagarkatti M and Nagarkatti PS (1997) Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood 89: 2901-2908
24. Ristamäki R, Joensuu H, Hagberg H, Kalkner KM and Jalkanen S (1998) Clinical significance of circulating CD44 in non-Hodgkin's lymphoma. Int J Cancer (Pred Oncol.) 79: 221-225
25. Ristamäki R, Joensuu H, Grön-Virta K, Salmi M and Jalkanen S (1997) Origin and function of circulating CD44 in non-Hodgkin's lymphoma. J Immunol 158: 3000-3008
26. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Geth U and Bell JI (1992) Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89: 12160-12164
27. Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A and Kainz C (1995) Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer 72: 1494-1497
28. Weg-Remers S, Hildebrandt U, Feifel G, Moser C, Zeitz M and Stallmach A (1998) Soluble CD44 and Cd44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6. Am J Gastroenterol 93: 790-794
29. Yu Q and Toole BP (1996) A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44. J Biol Chem 271: 20603-20607
30. Zeimer AG, Widschwendter M, Uhl-Steidl M, Muller-Holzner E, Daxenbichler G, Marth C and Dapunt O (1997) High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. Br J Cancer 76: 1646-1651